What is new in lymphoma?

被引:31
作者
Cheson, BD [1 ]
机构
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA
关键词
D O I
10.3322/canjclin.54.5.260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The lymphomas are a diverse group of malignant disorders that vary with respect to their molecular features, genetics, clinical presentation, treatment approaches, and outcome. Over the past few years, there have been major advances in our understanding of the biology of these diseases, leading to a universally adopted World Health Organization classification system. New therapies are now available with the potential to improve patient outcome, and the International Prognostic Index and standardized response criteria help make clinical trials interpretable. Most notably, the chimeric antiCD20 monoclonal antibody rituximab has altered our therapeutic paradigms for B-cell disorders. Combinations of this antibody with chemotherapy and other biologic agents have shown promise in treating lymphoma. Other antibodies, radioimmunoconjugates (such as Y-90 ibritumomab tiuxetan and 1-131 tositumomab), and oblimerson sodium (a BCL-2 antisense oligonucleotide) have all shown promise. New chemotherapy regimens such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), agents such as gemcitabine, and monoclonal antibodies directed against CD30 are also being studied in Hodgkin Lymphoma. The challenge of clinical research is to optimize the use of these agents, select patients most likely to respond, and develop multitargeted strategies based on sound scientific rational, with the potential to increase the cure rate of patients with lymphomas.
引用
收藏
页码:260 / 272
页数:13
相关论文
共 88 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]   Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma [J].
Ansell, SM ;
Ristow, KM ;
Habermann, TM ;
Wiseman, GA ;
Witzig, TE .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3885-3890
[3]  
Bartlett NL, 2003, BLOOD, V102, p647A
[4]  
Bennett JM, 2003, BLOOD, V102, p30A
[5]   Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].
Bohen, SP ;
Troyanskaya, OG ;
Alter, O ;
Warnke, R ;
Botstein, D ;
Brown, PO ;
Levy, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930
[6]  
BORDON LI, 2003, BLOOD, V102, pB307
[7]   High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas [J].
Bremer, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) :603-609
[8]   Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].
Byrd, JC ;
Murphy, T ;
Howard, RS ;
Lucas, MS ;
Goodrich, A ;
Park, K ;
Pearson, M ;
Waselenko, JK ;
Ling, G ;
Grever, MR ;
Grillo-Lopez, AJ ;
Rosenberg, J ;
Kunkel, L ;
Flinn, IW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164
[9]   Radioimmunotherapy of non-Hodgkin lymphomas [J].
Cheson, BD .
BLOOD, 2003, 101 (02) :391-398
[10]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253